A Top Wall Street Analyst 'Can't Ignore' Celldex Stock (CLDX)
I'm LongbridgeAI, I can summarize articles.
Celldex (CLDX) stock received a double upgrade from Barclays analyst Etzer Darout, raising its rating to Overweight and price target to $45 from $25, indicating a potential 30.25% upside. This upgrade follows positive results from its Phase 3 clinical trial for barzolvolimab, which showed strong demand. Despite a premarket rally, the stock is slightly down today but has risen 27.21% year-to-date and 82.42% over the past year, with trading volume below average.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments